

S3 Table. Association between the expression of METTL14, FTO and the clinicopathological characteristics in BC patients

Variable	No. of patients	Relative mRNA level of METTL14 (mean±SD)	p-value	Relative mRNA level of FTO (mean±SD)	p-value
Age (yr)					
< 50	22	13.820±7.366	0.341	2.881±4.687	0.479
≥ 50	38	12.530±8.693		2.115±2.242	
TNM					
0	5	13.510±4.690	0.955	1.797±0.989	0.960
I	10	14.360±9.163		1.709±1.232	
II	30	12.600±8.275		2.237±2.224	
III	6	11.100±6.478		1.733±1.631	
IV	2	16.930±12.080		1.248±0.537	
Stage					
0	5	13.510±4.690	0.640	1.797±0.989	>0.999
I -IV	55	12.950±8.465		2.450±3.469	
T category					
Tis	5	13.510±4.690	0.456	1.797±0.989	0.96
T1-T2	40	12.220±8.061		2.056±2.019	
T3-T4	6	16.530±8.524		2.062±1.689	
N category					
N0	33	12.240±7.452	0.109	1.859±1.230	0.225
N1	15	15.220±8.955		2.582±2.931	
N2-N3	4	6.049±4.045		0.886±0.808	
M category					
M0	57	13.080±8.054	0.540	2.477±3.398	0.592
M1	2	16.930±12.080		1.248±0.537	
TNBC					
Yes	8	18.000±10.930	0.157	1.772±1.076	0.873
No	52	12.230±7.531		2.492±3.553	
AFP (ng/mL)					
<6	57	13.180±8.259	0.475	2.427±3.412	0.975
≥6	3	9.579±7.153		1.812±1.144	
CEA (ng/mL)					
<5	52	13.270±8.106	0.410	2.353±3.445	0.790
≥5	8	11.250±9.100		2.672±2.665	
CA125 (IU/mL)					
<35	53	13.040±8.344	0.964	2.483±3.506	0.498
≥35	7	12.670±7.500		1.738±1.469	
CA153 (IU/mL)					
<25	57	13.340±8.258	0.133	2.448±3.411	0.749
≥25	3	6.627±2.428		1.398±0.620	

AFP, α -fetoprotein; ALKBH5, AlkB homolog 5; CA125, cancer antigen 125; CA153, carbohydrate antigen 153; CEA, carcinoembryonic antigen; FTO, fat mass and obesity-associated; METTL14, methyltransferase-like 14; WTAP, Wilms tumor 1 associated protein; SD, standard deviation.